Bookmark and Share

Celso  Arango
 

Celso Arango M.D., Ph.D.

Academic Title: Adjunct Professor
Primary Appointment: Psychiatry
carango@mprc.umaryland.edu
Location: 701 W. Pratt St., 388 (MPRC)

Personal History:

After completing his medical studies at the University of Oviedo in Spain and Manchester University in the UK (1992), he received his PhD in Psychiatry from Complutense University of Madrid (1997). He did a Residency in Psychiatry at the Hospital General Gregorio Marañón in Madrid (1993-1997), followed by a Research Fellowship at the University of Maryland School of Medicine in Baltimore. He is currently the Head of the Adolescent Unit, Department of Psychiatry, at Hospital General Universitario Gregorio Marañón, in Madrid, Spain, as well as Associate Professor of Psychiatry at the Maryland Psychiatric Research Center of the University of Maryland in Baltimore.

His awards include the Young Scientist Award at the 9th Biennial Winter Workshop on Schizophrenia in Davos, Switzerland (1997), the American Psychiatric Association Research Colloquium for Junior Investigators (Neuroimaging) in Toronto, Canada (1998), the Theodore and Vada Stanley Foundation Award (Prediction and prevention of violence in outpatient schizophrenia) (1999), the Young Scientist Award at the 11th Biennial Winter Workshop on Schizophrenia in Davos, Switzerland (2001), Independent investigator Award from the NARSAD (2005). He has received more than 12 research grants funded in competitive awards (PI in 8 of them) and is a member of the Editorial Board of five journals (including Schizophrenia Bulletin). He has published more than 50 papers in peer review journals and is editor of 3 books.

Research Interests:

Currently, his major research areas of interest are biological correlates of the different early onset psychoses and developmental neuropsychopharmacology. He is coordinator of the Spanish Network on Early Onset Psychosis, funded by the Spanish Department of Health and with 12 centers and more than 60 researchers involved in the network. The safety and tolerability of antipsychotics in children and adolescents is an active area of research of his group, which has published a number of papers on the subject in leading psychiatric journals.

His research methods include neuroimaging, neurophysiology and neuropsychopharmacology.


Publications:

Selected Publications from the Last 5 Years

Arango, C.; Kirkpatrick, B.; Buchanan, R.W. Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms. Journal of Nervous and Mental Disease, 188(1):50-3, 2000. (I.F.:1.44).

Arango, C.; Kirkpatrick, B.; Buchanan, R.W. Neurological signs and the heterogeneity of schizophrenia. American Journal of Psychiatry, 157 560-5, 2000. (I.F.:6.46).

Arango, C.; Kirkpatrick, B.; Koenig, J.I. At issue: stress, hippocampal neuronal turnover and neuropsychiatric disorders. Schizophrenia Bulletin, 27(3):477-80, 2001. (I.F.:3.21).

Arango, C.; Breier, A.; MacMahon, R.; Carpenter , W.; Buchanan, R.W. The relationship of clozapine and haloperidol treatment to prefrontal, hippocampal and caudate brain volumes. American Journal of Psychiatry, 160(8):1421-7, 2003. (I.F.:6.46).

Arango, C.; Summerfelt, A.; Buchanan, R.W. Olanzapine effects on auditory sensory gating in schizophrenia. American Journal of Psychiatry, 160(11): 2066-8, 2003. (I.F.:6.46).

Bombín, I.; Arango, C.; Buchanan, R.W. Assessment tools for soft signs. Psychiatric Annals , 33(3):1-8, 2003. (I.F.:1,08).

Buchanan, R.W.; Francis, A.; Arango, C.; Miller, K.; Lefkowitz, D.M.; McMahon, R.P.; Barta, P.E.; Pearlson, G.D. Morphometric assessment of the heteromodal cortex in schizophrenia. American Journal of Psychiatry, 161(2):322-31, 2004. (I.F.:6.46).

Arango, C.; Buchanan, R.W.; Kirkpatrick, B.; Carpenter, W.T. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. European Psychiatry, 19(1):21-6, 2004. (I.F.:1.33).

Arango, C.; Parellada, M.; Moreno, D.M. Clinical effectiveness of new generation antipsychotics in adolescent patients. European Neuropsychopharmacology, 14: S471-9, 2004. (I.F.:2.84).

Bombín, I.; Arango, C.; Buchanan, R.W. Significance and meaning of neurological signs in schizophrenia: 15 years later. Schizophrenia Bulletin. 31(4):962-77, 2005. (I.F.:2.64).

Meza, N.; Rossi, N.; Galeazzi, T.; Sánchez, N.; Colmenares, F.; Medina, O.; Uzcategui, N.; Alfonzo, N; Arango, C.; Urdaneta, H. Cysticercosis in psychiatric inpatients: Prevalence of cysticercosis in chronic psychiatric inpatients from a venezuelan community. Am J Trop Med Hyg. 73:504-9, 2005. (I.F.: 2.105).

Moreno D, Burdalo M, Reig S, Parellada M, Zabala A, Desco M, Baca-Baldomero E, Arango C. Structural Neuroimaging in Adolescents With a First Psychotic Episode. J Am Acad Child Adolesc Psychiatry. 2005; 44:1151-1157.

Artaloytia, J.F.; Arango, C.; Lahti, A.; Sanz, J.; Pascual, A.; Cubero, P.; Prieto, D.; Palomo, T. Negative signs and symtoms secondary to antipsychotics: A double-blind randomized trial of single dose of placebo, haloperidol and risperidone in healthy volunteers. The American Journal of Psychiatry. (I.F.: 7.16). (in press). (I.F.: 3.66).

J. van Os, T. Burns, R. Cavallaro, S. Leucht, J. Peuskens, L. Helldin, M. Bernardo, C. Arango, W. Fleischhacker, B. Lachaux, J. M. Kane. Standardised remission criteria in schizophrenia. Acta Psychiatrica Scandinavica. (I.F.: 2,356). (in press).